<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03765593</url>
  </required_header>
  <id_info>
    <org_study_id>3398</org_study_id>
    <nct_id>NCT03765593</nct_id>
  </id_info>
  <brief_title>Biomarkers in Primary Sjögren's Syndrome</brief_title>
  <acronym>pSS</acronym>
  <official_title>Gene Expression of Interferon (INF) and B Lymphocyte Biomarkers as Markers of Systemic Affectation and Lymphoproliferative Disease in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Council of Scientific and Technical Research, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Council of Scientific and Technical Research, Argentina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical spectrum of primary Sjogren Syndrome (pSS)ranges from sicca syndrome to systemic&#xD;
      involvement (extraglandular manifestations), including a large number of manifestations that&#xD;
      may be the form of presentation or appear after the disease is diagnosed, and that clearly&#xD;
      mark the prognosis of the disease.&#xD;
&#xD;
      Gene expression levels of Interferon (INF) and B Lymphocyte Biomarkers as Markers of Systemic&#xD;
      Affectation and Lymphoproliferative Disease in, together with clinical and laboratory&#xD;
      parameters, will provide significant information about the risk of developing hematological&#xD;
      neoplasms in patients with pSS at different stages of the disease, and lead to better&#xD;
      management of the disease treatment and therapeutic behaviors.&#xD;
&#xD;
      Using the proposed technique allows us to study the gene expression at the mRNA level of each&#xD;
      biomarker, which allows us to anticipate the irreversible changes that take place due to the&#xD;
      progress of the pathology in progress, since the molecular changes precede the histological&#xD;
      changes and in the pathological diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project, address the value of these proposed biomarkers in pSS with regard to disease&#xD;
      activity and risk stratification of pSS subsets. The investigator's group aim to determine if&#xD;
      the proposed biomarkers and their gene expression in saliva, peripheral blood and minor&#xD;
      salivary gland samples in patients with pSS are increased to know the degree of their&#xD;
      usefulness in daily clinical practice, to indicate which patients have a highest risk of&#xD;
      developing a hematological malignancy and to know if these biomarkers are useful to recognize&#xD;
      patients who have greater activity of the disease to be able to use it in the follow-up of&#xD;
      the disease and as a future responder of the new biological therapies against B cells, INF&#xD;
      and monocytes.&#xD;
&#xD;
      Gene expression is a highly regulated mechanism that controls the function and adaptability&#xD;
      of all living cells. The field of gene expression analysis has undergone important advances&#xD;
      in biomedical research. Today, quantification techniques of mRNA expression have led to&#xD;
      improvements in the identification of the gene and the sub-classification of the disease, for&#xD;
      example, the expression of specific genes (mRNA) can be quantified by reverse transcription&#xD;
      and PCR in quantitative real time. This is the most sensitive technique available to detect&#xD;
      and quantify mRNA, where extremely small sample sizes can be used in mRNA quantification.&#xD;
      Molecular changes precede histological changes and clinicians in the diagnosis of a&#xD;
      pathology. For this reason, studying gene expression at the mRNA level allows us to&#xD;
      anticipate irreversible changes that take place due to the progress of the pathology in&#xD;
      progress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in salivary gland biopsy samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in blood samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression levels in immune cells in saliva samples from participants with and without pSS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulins</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in IgG, IgM and IgA levels at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement levels C3 and C4</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in complement levels at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Factor</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in titer of rheumatoid factors at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryoglobulins</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The change from baseline in titer of cryoglobulins at 24 months.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Sjögren Syndrome</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Study group 1</arm_group_label>
    <description>Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 2</arm_group_label>
    <description>Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 3</arm_group_label>
    <description>Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy Salivary Gland</intervention_name>
    <description>A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group 1</arm_group_label>
    <arm_group_label>Study group 2</arm_group_label>
    <arm_group_label>Study group 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Salivary gland, saliva, blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with sicca and primary Sjogren Syndrome will be recruited from multiple sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients: cross sectionally patients will be included for clinical suspicion of&#xD;
             primary SS or with the diagnosis already established in Rheumatology unit.&#xD;
&#xD;
        The following inclusion criteria will be applied to the study:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed consent of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility of obtaining consent (cognitive impairment, other causes).&#xD;
&#xD;
          -  Associated systemic autoimmune or rheumatological diseases.&#xD;
&#xD;
          -  Chronic viral infections (HCV, HBV, HIV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Soledad Retamozo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INICSA-Universidad Nacional de Córdoba-CONICET, Córdoba, Argentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Soledad Retamozo, MD, PhD</last_name>
    <phone>005493516981622</phone>
    <email>soleretamozo@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Cuestas, MD, PhD</last_name>
    <phone>005493516609303</phone>
    <email>eduardo.cuestas@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Retamozo S, Flores-Chavez A, Consuegra-Fernandez M, Lozano F, Ramos-Casals M, Brito-Zeron P. Cytokines as therapeutic targets in primary Sjogren syndrome. Pharmacol Ther. 2018 Apr;184:81-97. doi: 10.1016/j.pharmthera.2017.10.019. Epub 2017 Oct 29.</citation>
    <PMID>29092775</PMID>
  </reference>
  <reference>
    <citation>Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;89(6):888-92. doi: 10.7326/0003-4819-89-6-888.</citation>
    <PMID>102228</PMID>
  </reference>
  <reference>
    <citation>Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep. 2003 Aug;5(4):311-6. doi: 10.1007/s11926-003-0010-z.</citation>
    <PMID>14531959</PMID>
  </reference>
  <reference>
    <citation>Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002 Mar;46(3):741-7. doi: 10.1002/art.10221.</citation>
    <PMID>11920410</PMID>
  </reference>
  <reference>
    <citation>Brito-Zeron P, Retamozo S, Gheitasi H, Ramos-Casals M. Erratum to: Treating the Underlying Pathophysiology of Primary Sjogren Syndrome: Recent Advances and Future Prospects. Drugs. 2016 Dec;76(18):1799. doi: 10.1007/s40265-016-0669-x. No abstract available.</citation>
    <PMID>27905085</PMID>
  </reference>
  <reference>
    <citation>Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013 Oct;72(10):1639-45. doi: 10.1136/annrheumdis-2012-201586. Epub 2012 Oct 31.</citation>
    <PMID>23117242</PMID>
  </reference>
  <results_reference>
    <citation>Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 2000 Apr;43(4):908-16. doi: 10.1002/1529-0131(200004)43:43.0.CO;2-K.</citation>
    <PMID>10765938</PMID>
  </results_reference>
  <results_reference>
    <citation>Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA/SSB-negative Sjogren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015 Nov;14(11):1019-22. doi: 10.1016/j.autrev.2015.07.002. Epub 2015 Jul 8.</citation>
    <PMID>26162302</PMID>
  </results_reference>
  <results_reference>
    <citation>Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, De Vita S. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;52(2):276-81. doi: 10.1093/rheumatology/kes180. Epub 2012 Aug 9.</citation>
    <PMID>22879463</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3. doi: 10.1126/science.285.5425.260.</citation>
    <PMID>10398604</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747-56. doi: 10.1084/jem.189.11.1747.</citation>
    <PMID>10359578</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003 Feb;62(2):168-71. doi: 10.1136/ard.62.2.168.</citation>
    <PMID>12525388</PMID>
  </results_reference>
  <results_reference>
    <citation>Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis. 2011 Aug;70(8):1363-8. doi: 10.1136/ard.2010.144782.</citation>
    <PMID>21715359</PMID>
  </results_reference>
  <results_reference>
    <citation>Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol. 2004 Apr;202(4):496-502. doi: 10.1002/path.1533.</citation>
    <PMID>15095277</PMID>
  </results_reference>
  <results_reference>
    <citation>Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol. 2005 Nov;117(2):168-76. doi: 10.1016/j.clim.2005.06.016. Epub 2005 Aug 26.</citation>
    <PMID>16126006</PMID>
  </results_reference>
  <results_reference>
    <citation>Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. 2007 Apr;56(4):1134-44. doi: 10.1002/art.22458.</citation>
    <PMID>17393395</PMID>
  </results_reference>
  <results_reference>
    <citation>Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005 May;52(5):1534-44. doi: 10.1002/art.21006.</citation>
    <PMID>15880807</PMID>
  </results_reference>
  <results_reference>
    <citation>Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008 Jul;38(7):2024-33. doi: 10.1002/eji.200738008.</citation>
    <PMID>18581327</PMID>
  </results_reference>
  <results_reference>
    <citation>Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, Wildenberg ME, Beumer W, Drexhage HA, Versnel MA. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013 May;72(5):728-35. doi: 10.1136/annrheumdis-2012-201381. Epub 2012 Jun 26.</citation>
    <PMID>22736090</PMID>
  </results_reference>
  <results_reference>
    <citation>Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14.</citation>
    <PMID>26183766</PMID>
  </results_reference>
  <results_reference>
    <citation>Rose T, Szelinski F, Lisney A, Reiter K, Fleischer SJ, Burmester GR, Radbruch A, Hiepe F, Grutzkau A, Biesen R, Dorner T. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome. RMD Open. 2016 Dec 30;2(2):e000292. doi: 10.1136/rmdopen-2016-000292. eCollection 2016.</citation>
    <PMID>28123773</PMID>
  </results_reference>
  <results_reference>
    <citation>Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 2005 Jun;52(6):1773-84. doi: 10.1002/art.21062.</citation>
    <PMID>15934082</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Council of Scientific and Technical Research, Argentina</investigator_affiliation>
    <investigator_full_name>Maria Soledad Retamozo</investigator_full_name>
    <investigator_title>Research Assistant</investigator_title>
  </responsible_party>
  <keyword>Primary Sjogren Syndrome</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03765593
org study id: 3398
nct id: NCT03765593
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The clinical spectrum of primary Sjogren Syndrome (pSS)ranges from sicca syndrome to systemic
      involvement (extraglandular manifestations), including a large number of manifestations that
      may be the form of presentation or appear after the disease is diagnosed, and that clearly
      mark the prognosis of the disease.

      Gene expression levels of Interferon (INF) and B Lymphocyte Biomarkers as Markers of Systemic
      Affectation and Lymphoproliferative Disease in, together with clinical and laboratory
      parameters, will provide significant information about the risk of developing hematological
      neoplasms in patients with pSS at different stages of the disease, and lead to better
      management of the disease treatment and therapeutic behaviors.

      Using the proposed technique allows us to study the gene expression at the mRNA level of each
      biomarker, which allows us to anticipate the irreversible changes that take place due to the
      progress of the pathology in progress, since the molecular changes precede the histological
      changes and in the pathological diagnosis.
This project, address the value of these proposed biomarkers in pSS with regard to disease
      activity and risk stratification of pSS subsets. The investigator's group aim to determine if
      the proposed biomarkers and their gene expression in saliva, peripheral blood and minor
      salivary gland samples in patients with pSS are increased to know the degree of their
      usefulness in daily clinical practice, to indicate which patients have a highest risk of
      developing a hematological malignancy and to know if these biomarkers are useful to recognize
      patients who have greater activity of the disease to be able to use it in the follow-up of
      the disease and as a future responder of the new biological therapies against B cells, INF
      and monocytes.

      Gene expression is a highly regulated mechanism that controls the function and adaptability
      of all living cells. The field of gene expression analysis has undergone important advances
      in biomedical research. Today, quantification techniques of mRNA expression have led to
      improvements in the identification of the gene and the sub-classification of the disease, for
      example, the expression of specific genes (mRNA) can be quantified by reverse transcription
      and PCR in quantitative real time. This is the most sensitive technique available to detect
      and quantify mRNA, where extremely small sample sizes can be used in mRNA quantification.
      Molecular changes precede histological changes and clinicians in the diagnosis of a
      pathology. For this reason, studying gene expression at the mRNA level allows us to
      anticipate irreversible changes that take place due to the progress of the pathology in
      progress.
observational model: Cohort
time perspective: Prospective
measure: Gene expression levels in immune cells in salivary gland biopsy samples from participants with and without pSS
time frame: Up to 24 months
description: To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).
measure: Gene expression levels in immune cells in blood samples from participants with and without pSS
time frame: Up to 24 months
description: To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).
measure: Gene expression levels in immune cells in saliva samples from participants with and without pSS
time frame: Up to 24 months
description: To identify a biomarker of disease activity, measured by the real-time PCR reactions (qRT-PCR).
measure: Immunoglobulins
time frame: Up to 24 months
description: The change from baseline in IgG, IgM and IgA levels at 24 months.
measure: Complement levels C3 and C4
time frame: Up to 24 months
description: The change from baseline in complement levels at 24 months.
measure: Rheumatoid Factor
time frame: Up to 24 months
description: The change from baseline in titer of rheumatoid factors at 24 months.
measure: Cryoglobulins
time frame: Up to 24 months
description: The change from baseline in titer of cryoglobulins at 24 months.
arm group label: Study group 1
description: Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
arm group label: Study group 2
description: Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
arm group label: Study group 3
description: Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
arm group label: Control group
description: Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
intervention type: Procedure
intervention name: Biopsy Salivary Gland
description: A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
arm group label: Control group
arm group label: Study group 1
arm group label: Study group 2
arm group label: Study group 3
Salivary gland, saliva, blood samples
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Maria Soledad Retamozo, MD, PhD
role: Principal Investigator
affiliation: INICSA-Universidad Nacional de Córdoba-CONICET, Córdoba, Argentina
last name: Maria Soledad Retamozo, MD, PhD
phone: 005493516981622
email: soleretamozo@hotmail.com
last name: Eduardo Cuestas, MD, PhD
phone: 005493516609303
email: eduardo.cuestas@gmail.com
citation: Retamozo S, Flores-Chavez A, Consuegra-Fernandez M, Lozano F, Ramos-Casals M, Brito-Zeron P. Cytokines as therapeutic targets in primary Sjogren syndrome. Pharmacol Ther. 2018 Apr;184:81-97. doi: 10.1016/j.pharmthera.2017.10.019. Epub 2017 Oct 29.
PMID: 29092775
citation: Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;89(6):888-92. doi: 10.7326/0003-4819-89-6-888.
PMID: 102228
citation: Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep. 2003 Aug;5(4):311-6. doi: 10.1007/s11926-003-0010-z.
PMID: 14531959
citation: Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002 Mar;46(3):741-7. doi: 10.1002/art.10221.
PMID: 11920410
citation: Brito-Zeron P, Retamozo S, Gheitasi H, Ramos-Casals M. Erratum to: Treating the Underlying Pathophysiology of Primary Sjogren Syndrome: Recent Advances and Future Prospects. Drugs. 2016 Dec;76(18):1799. doi: 10.1007/s40265-016-0669-x. No abstract available.
PMID: 27905085
citation: Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013 Oct;72(10):1639-45. doi: 10.1136/annrheumdis-2012-201586. Epub 2012 Oct 31.
PMID: 23117242
citation: Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 2000 Apr;43(4):908-16. doi: 10.1002/1529-0131(200004)43:43.0.CO;2-K.
PMID: 10765938
citation: Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA/SSB-negative Sjogren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015 Nov;14(11):1019-22. doi: 10.1016/j.autrev.2015.07.002. Epub 2015 Jul 8.
PMID: 26162302
citation: Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, De Vita S. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;52(2):276-81. doi: 10.1093/rheumatology/kes180. Epub 2012 Aug 9.
PMID: 22879463
citation: Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3. doi: 10.1126/science.285.5425.260.
PMID: 10398604
citation: Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747-56. doi: 10.1084/jem.189.11.1747.
PMID: 10359578
citation: Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003 Feb;62(2):168-71. doi: 10.1136/ard.62.2.168.
PMID: 12525388
citation: Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis. 2011 Aug;70(8):1363-8. doi: 10.1136/ard.2010.144782.
PMID: 21715359
citation: Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol. 2004 Apr;202(4):496-502. doi: 10.1002/path.1533.
PMID: 15095277
citation: Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol. 2005 Nov;117(2):168-76. doi: 10.1016/j.clim.2005.06.016. Epub 2005 Aug 26.
PMID: 16126006
citation: Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. 2007 Apr;56(4):1134-44. doi: 10.1002/art.22458.
PMID: 17393395
citation: Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005 May;52(5):1534-44. doi: 10.1002/art.21006.
PMID: 15880807
citation: Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008 Jul;38(7):2024-33. doi: 10.1002/eji.200738008.
PMID: 18581327
citation: Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, Wildenberg ME, Beumer W, Drexhage HA, Versnel MA. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013 May;72(5):728-35. doi: 10.1136/annrheumdis-2012-201381. Epub 2012 Jun 26.
PMID: 22736090
citation: Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14.
PMID: 26183766
citation: Rose T, Szelinski F, Lisney A, Reiter K, Fleischer SJ, Burmester GR, Radbruch A, Hiepe F, Grutzkau A, Biesen R, Dorner T. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome. RMD Open. 2016 Dec 30;2(2):e000292. doi: 10.1136/rmdopen-2016-000292. eCollection 2016.
PMID: 28123773
citation: Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 2005 Jun;52(6):1773-84. doi: 10.1002/art.21062.
PMID: 15934082
responsible party type: Principal Investigator
investigator affiliation: National Council of Scientific and Technical Research, Argentina
investigator full name: Maria Soledad Retamozo
investigator title: Research Assistant
mesh term: Lymphoma, Non-Hodgkin
mesh term: Sjogren's Syndrome
mesh term: Syndrome
sharing ipd: No